​

Gilead Sciences (GILD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

GILD Stock Forecast

Gilead Sciences (GILD) stock forecast, based on 58 Wall Street analysts, predicts a 12-month average price target of $155.50, with a high of $180.00 and a low of $123.00. This represents a 16.73% increase from the last price of $133.21.

$50 $80 $110 $140 $170 $200 High: $180 Avg: $155.5 Low: $123 Last Closed Price: $133.21

GILD Stock Rating

Gilead Sciences stock's rating consensus is Buy, based on 58 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 39 Buy (67.24%), 18 Hold (31.03%), 1 Sell (1.72%), and 0 Strong Sell (0.00%).

Buy
Total 58 1 18 39 Strong Sell Sell Hold Buy Strong Buy

GILD Price Target Upside V Benchmarks

TypeNameUpside
StockGilead Sciences16.73%
SectorHealthcare Stocks 15.45%
IndustryDrug Manufacturers - General Stocks9.20%

Price Target Trends

1M3M12M
# Anlaysts51046
Avg Price Target$142.00$143.80$151.22
Last Closing Price$133.21$133.21$133.21
Upside/Downside6.60%7.95%13.52%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Aug, 266167--29
Jul, 266167--29
Jun, 266187--31
May, 265178--30
Apr, 265188--31
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 05, 2026Truist Financial$150.00$132.7612.99%12.60%
Aug 05, 2026RBC Capital$123.00$135.25-9.06%-7.66%
Jul 29, 2026Barclays$145.00$134.327.95%8.85%
Jul 27, 2026Morgan Stanley$165.00$131.2325.73%23.86%
Jul 20, 2026Daina GrayboschLeerink Partners$127.00$133.21-4.66%-4.66%
Jul 08, 2026Morgan Stanley$166.00$136.3621.74%24.62%
Jul 07, 2026Brian AbrahamsRBC Capital$120.00$129.61-7.41%-9.92%
Jul 06, 2026Rajesh KumarHSBC$155.00$131.2718.08%16.36%
Jun 01, 2026Brian AbrahamsRBC Capital$122.00$134.43-9.25%-8.42%
May 20, 2026Michael OkunewitchMaxim Group$165.00$130.5526.39%23.86%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 05, 2026RBC CapitalSector PerformSector Performhold
Jul 29, 2026Cantor FitzgeraldOverweightOverweighthold
Jul 07, 2026RBC CapitalSector PerformSector Performhold
Jul 06, 2026HSBCHoldBuyupgrade
Jun 09, 2026Cantor FitzgeraldOverweightOverweighthold
Jun 08, 2026RBC CapitalSector PerformSector Performhold
Jun 01, 2026RBC CapitalOverweightOverweighthold
Apr 10, 2026Morgan StanleyOverweightOverweighthold
Mar 10, 2026JefferiesBuyBuyinitialise
Mar 06, 2026Bank of America SecuritiesBuyBuyhold

Financial Forecast

EPS Forecast

$0 $2 $4 $6 $8 $10 $11 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.96$3.66$4.54$0.38$6.84---
Avg Forecast$8.20$7.10$6.75$4.38$7.59$7.95$8.47$9.07
High Forecast$8.53$7.42$7.05$4.72$8.42$9.84$10.05$9.61
Low Forecast$7.96$6.84$6.58$3.87$6.40$5.77$5.94$8.66
Surprise %-39.51%-48.45%-32.74%-91.32%-9.88%---

Revenue Forecast

$26B $27B $29B $31B $32B $34B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$27.30B$27.28B$27.12B$28.75B$29.44B---
Avg Forecast$26.67B$26.53B$27.10B$28.32B$28.49B$29.34B$30.74B$32.22B
High Forecast$27.48B$27.44B$27.28B$28.60B$29.85B$29.36B$30.85B$33.68B
Low Forecast$26.05B$25.78B$26.91B$28.10B$27.87B$29.31B$30.63B$31.10B
Surprise %2.38%2.84%0.06%1.54%3.34%---

Net Income Forecast

$0 $3B $6B $9B $12B $15B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.22B$4.59B$5.67B$480.00M$8.51B---
Avg Forecast$5.09B$3.23B$5.67B$5.40B$9.33B$7.55B$8.20B$11.41B
High Forecast$6.10B$3.88B$6.80B$5.94B$10.60B$12.37B$12.64B$12.09B
Low Forecast$4.07B$2.58B$4.53B$4.87B$8.06B$7.26B$7.47B$10.90B
Surprise %22.36%42.16%--91.12%-8.75%---

GILD Forecast FAQ

Is Gilead Sciences stock a buy?

Gilead Sciences stock has a consensus rating of Buy, based on 58 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 39 Buy, 18 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Gilead Sciences is a favorable investment for most analysts.

What is Gilead Sciences's price target?

Gilead Sciences's price target, set by 58 Wall Street analysts, averages $155.5 over the next 12 months. The price target range spans from $123 at the low end to $180 at the high end, suggesting a potential 16.73% change from the previous closing price of $133.21.

How does Gilead Sciences stock forecast compare to its benchmarks?

Gilead Sciences's stock forecast shows a 16.73% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the drug manufacturers - general stocks industry (9.20%).

What is the breakdown of analyst ratings for Gilead Sciences over the past three months?

  • August 2026: 20.69% Strong Buy, 55.17% Buy, 24.14% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 20.69% Strong Buy, 55.17% Buy, 24.14% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 19.35% Strong Buy, 58.06% Buy, 22.58% Hold, 0% Sell, 0% Strong Sell.

What is Gilead Sciences’s EPS forecast?

Gilead Sciences's average annual EPS forecast for its fiscal year ending in December 2026 is $7.95, marking a 16.23% increase from the reported $6.84 in 2025. Estimates for the following years are $8.47 in 2027, and $9.07 in 2028.

What is Gilead Sciences’s revenue forecast?

Gilead Sciences's average annual revenue forecast for its fiscal year ending in December 2026 is $29.34B, reflecting a -0.37% decrease from the reported $29.44B in 2025. The forecast for 2027 is $30.74B, and $32.22B for 2028.

What is Gilead Sciences’s net income forecast?

Gilead Sciences's net income forecast for the fiscal year ending in December 2026 stands at $7.55B, representing a -11.31% decrease from the reported $8.51B in 2025. Projections indicate $8.2B in 2027, and $11.41B in 2028.